News

EV2 lands $2.1M NIH grant for biodegradable artery device

What's the deal? EV2 Technologies, a University of Pittsburgh-based startup, won a two-year, $2.1 million Small Business Innovation Research (SBIR) Direct-to-Phase II award from the National Institutes of Health's National Heart, Lung, and Blood InstituteDealroom has a profile for this one. Try Dealroom →. The grant funds Biocarpet, a fully biodegradable sheet that unfurls inside blood vessels to clear blockages caused by peripheral artery disease (PAD).

What's the endgame? Conventional stents struggle in small or winding arteries and often fail after implantation, especially in vessels that cross joints. Biocarpet is designed to conform to complex vascular anatomy and cut the likelihood of restenosis.

Why now? PAD affects more than 12 million Americans and 200 million people worldwide, and demand for better treatment is rising. The award follows a 2023 NIH Catalyze grant that let the team skip the traditional Phase I SBIR process.

What's the money for? Over two years, EV2 will refine manufacturing for scale, redesign the thermal balloon catheter that delivers the device, and build a control console compatible with any catheterisation lab. The work includes benchtop testing and a six-month animal study to assess safety and efficacy.

The company grew from years of research led by chief executive officer Ali Behrangzade and co-founders including professors Jonathan Vande Geest, William R. Wagner, and John Pacella. "Blood vessels aren't just straight tubes, and as we age, they can become a very complex biomechanical environment," Vande Geest said.

The award also lets EV2 formally license the underlying technology from the university for the first time. "Given the nature of our work, we're pursuing a hybrid approach between private and federal fundraising," Behrangzade said, adding that the company will keep seeking grants while talking to venture capitalists.

The signal: Non-dilutive federal funding remains a critical runway for early-stage medtech, bridging lab research toward commercial development before private capital steps in.

Read more: engineering.pitt.edu

Image credit: Generated with Gemini

More top stories